Dataset Information

Anti-Tumor Necrosis Factor ? Therapeutics Differentially Affect Leishmania Infection of Human Macrophages.

ABSTRACT: Tumor necrosis factor ? (TNF?) drives the pathophysiology of human autoimmune diseases and consequently, neutralizing antibodies (Abs) or Ab-derived molecules directed against TNF? are essential therapeutics. As treatment with several TNF? blockers has been reported to entail a higher risk of infectious diseases such as leishmaniasis, we established an in vitro model based on Leishmania-infected human macrophages, co-cultured with autologous T-cells, for the analysis and comparison of anti-TNF? therapeutics. We demonstrate that neutralization of soluble TNF? (sTNF?) by the anti-TNF? Abs Humira^®, Remicade^®, and its biosimilar Remsima^® negatively affects infection as treatment with these agents significantly reduces Leishmania-induced T-cell proliferation and increases the number of infected macrophages. By contrast, we show that blockade of sTNF? by Cimzia^® does not affect T-cell proliferation and infection rates. Moreover, compared to Remicade^®, treatment with Cimzia^® does not impair the expression of cytolytic effector proteins in proliferating T-cells. Our data demonstrate that Cimzia^® supports parasite control through its conjugated polyethylene glycol (PEG) moiety as PEGylation of Remicade^® improves the clearance of intracellular Leishmania. This effect can be linked to complement activation, with levels of complement component C5a being increased upon treatment with Cimzia^® or a PEGylated form of Remicade^®. Taken together, we provide an in vitro model of human leishmaniasis that allows direct comparison of different anti-TNF? agents. Our results enhance the understanding of the efficacy and adverse effects of TNF? blockers and they contribute to evaluate anti-TNF? therapy for patients living in countries with a high prevalence of leishmaniasis.

SUBMITTER: Arens K

PROVIDER: S-EPMC6079256 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Anti-Tumor Necrosis Factor α Therapeutics Differentially Affect Leishmania Infection of Human Macrophages.

Arens Katharina K Filippis Christodoulos C Kleinfelder Helen H Goetzee Arthur A Reichmann Gabriele G Crauwels Peter P Waibler Zoe Z Bagola Katrin K van Zandbergen Ger G

Frontiers in immunology 20180731

Tumor necrosis factor α (TNFα) drives the pathophysiology of human autoimmune diseases and consequently, neutralizing antibodies (Abs) or Ab-derived molecules directed against TNFα are essential therapeutics. As treatment with several TNFα blockers has been reported to entail a higher risk of infectious diseases such as leishmaniasis, we established an in vitro model based on Leishmania-infected human macrophages, co-cultured with autologous T-cells, for the analysis and comparison ...[more]

PMID: 30108591

Similar Datasets

Project description:Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) is an anti-inflammatory protein implicated in multiple autoimmune and rheumatologic conditions. We hypothesized that lower levels of TNFAIP3 contributes to excessive cytokine production in response to inflammatory stimuli in axial spondyloarthritis (AxSpA). A further aim was to determine the immune signaling and genetic variation regulating TNFAIP3 expression in individual subjects.Blood-derived macrophages from 50 AxSpA subjects and 30 healthy controls were assessed for TNFAIP3 expression. Cell lysates were also analyzed for NF-?B, mitogen-activated protein (MAP) kinase and STAT3 phosphorylation, and supernatants for cytokine production. Coding and regulatory regions in the TNFAIP3 gene and other auto-inflammation-implicated genes were sequenced by next-generation sequencing and variants identified.Mean TNFAIP3 was significantly lower in spondyloarthritis macrophages than controls (p?=?0.0085). Spondyloarthritis subject macrophages correspondingly produced more TNF-? in response to lipopolysaccharide (LPS, p?=?0.015). Subjects with the highest TNFAIP3 produced significantly less TNF-? in response to LPS (p?=?0.0023). Within AxSpA subjects, those on TNF blockers or with shorter duration of disease expressed lower levels of TNFAIP3 (p?=?0.0011 and 0.0030, respectively). TNFAIP3 expression correlated positively with phosphorylated I?B?, phosphorylated MAP kinases, and unstimulated phosphorylated STAT3, but negatively with LPS or TNF-?-stimulated fold induction of phosphorylated STAT3. Further, subjects with specific groups of variants within TNFAIP3 displayed differences in TNFAIP3 (p?=?0.03-0.004). Nominal pQTL associations with genetic variants outside TNFAIP3 were identified.Our results suggest that both immune functional and genetic variations contribute to the regulation of TNFAIP3 levels in individual subjects. Decreased expression of TNFAIP3 in AxSpA macrophages correlated with increased LPS-induced TNF-?, and thus, TNFAIP3 dysregulation may be a contributor to excessive inflammatory responses in spondyloarthritis subjects.

Dataset Information

Anti-Tumor Necrosis Factor ? Therapeutics Differentially Affect Leishmania Infection of Human Macrophages.

Publications

Anti-Tumor Necrosis Factor α Therapeutics Differentially Affect <i>Leishmania</i> Infection of Human Macrophages.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets